Assessment of Measurable Residual Disease (MRD) in Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) Among US Community Hematologists/ Oncologists (cH/O)

被引：0
|
作者：
Gajra, Ajeet
Rathish, Yamini S.
Jeune-Smith, Yolaine
Klink, Andrew J.
Feinberg, Bruce
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-142005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] ROR-1 Is a Highly Discriminative Marker in Flow Cytometric Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL)
    Patz, Michaela
    Pentok, Barbara
    Cremer, Kathrin
    Linnartz, Stefanie
    Lilienweiss, Esther
    Kleinert, Fanni
    Hallek, Michael
    Kreuzer, Karl-Anton
    BLOOD, 2016, 128 (22)
  • [32] Racial and Socioeconomic Disparities Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated in the US Community Oncology Setting
    Su, Zhaohui
    O'Sullivan, Amy K.
    Marcus, Ari
    Zackon, Ira L.
    BLOOD, 2023, 142
  • [33] Barriers to Referral for Chimeric Antigen Receptor T Cell (CAR-T) Therapies Among US Community Hematologists/Oncologists (cH/O)
    Gajra, Ajeet
    Jeune-Smith, Yolaine
    Feinberg, Bruce A.
    BLOOD, 2021, 138
  • [34] Patterns of graft-versus-leukemia-mediated minimal residual disease (MRD) eradication in patients allografted for poor-risk chronic lymphocytic leukemia (CLL)
    Hahn, M.
    Boettcher, S.
    Dietrich, S.
    Herth, I.
    Hegenbart, U.
    Rieger, M.
    Stadtherr, P.
    Bondong, A.
    Ritgen, M.
    Zenz, T.
    Kneba, M.
    Ho, A. D.
    Dreger, P.
    ONKOLOGIE, 2013, 36 : 58 - 58
  • [35] Clinical significance of minimal residual disease (MRD), as assessed by different techniques, after stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL)
    Moreno, C
    Villamor, N
    Esteve, J
    Colomer, D
    Bosch, F
    Carnpo, E
    Montserrat, E
    BLOOD, 2005, 106 (11) : 571A - 571A
  • [36] Recent enhancements of minimal residual disease detection by flow-cytometry in chronic lymphocytic leukemia: a study of the French CLL-MRD group
    Dahmani, Abdelmalek
    Arnoulet, Christine
    Baseggio, Lucile
    Campos, Lydia
    Chatelain, Bernard
    Debliquis, Agathe
    Drenou, Bernard
    Jacob, Marie-Christine
    Legac, Eric
    Le Garff-Tavernier, Magali
    Quiney, Claire
    Robillard, Nelly
    Solly, Francoise
    Ticchioni, Michel
    Cartron, Guillaume
    Dartigeas, Caroline
    Feugier, Pierre
    Leblond, Veronique
    Lepretre, Stephane
    Van den Neste, Eric
    Delfau-Larue, Marie-Helene
    Cymbalista, Florence
    Letestu, Remi
    LEUKEMIA & LYMPHOMA, 2015, 56 : 115 - 116
  • [37] A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable Measurable Residual Disease (MRD) in Transplant-Eligible Multiple Myeloma (MM)
    Guerrero, Camila
    Puig, Noemi
    Cedena, Maria Teresa
    Goicoechea, Ibai
    Ruiz, Cristina Perez
    Garces, Juan Jose
    Botta, Cirino
    Calasanz, Maria Jose
    Gutierrez, Norma C.
    Martin-Ramos, Maria Luisa
    Oriol, Albert
    Rios, Rafael
    Hernandez, Miguel
    Martinez, Rafael
    Bargay, Joan
    De Arriba, Felipe
    Palomera, Luis
    Gonzalez, Ana Pilar
    Orgueira, Adrian Mosquera
    Gonzalez, Marta Sonia
    Martinez-Lopez, Joaquin
    Lahuerta, Juan Jose
    Rosinol, Laura
    Creixenti, Joan Blade
    Mateos, Maria-Victoria
    San-Miguel, Jesus
    Paiva, Bruno
    BLOOD, 2021, 138
  • [38] A machine learning model based on tumor and immune biomarkers to predict undetectable measurable residual disease (MRD) in transplant-eligible multiple myeloma (MM)
    Guerrero, Camila
    Puig, Noemi
    Teresa Cedena, Maria
    Goicoechea, Ibai
    Perez, Cristina
    Jose Garces, Juan
    Botta, Cirino
    Jose Calasanz, Maria
    Gutierrez, Norma C.
    Martin Ramos, Maria Luisa
    Oriol, A.
    Rios, Rafael
    Teodoro Hernandez, Miguel
    Martinez Martinez, Rafael
    Bargay, Joan
    de Arriba, Felipe
    Palomera, Luis
    Gonzalez Rodriguez, Ana Pilar
    Martinez-Lopez, Joaquin
    Jose Lahuerta, Juan
    Rosinol, Laura
    Blade, J.
    Mateos, Maria-Victoria
    San-Miguel, Jesus F.
    Paiva, Bruno
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S35 - S35
  • [39] Advanced circulating tumor DNA (ctDNA) Profiling: Enhancing Non-Invasive Detection and Characterization of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)
    Buenache, Natalia
    Martin-Munoz, Alejandro
    Ruiz-Heredia, Yanira
    Lasa, Marta
    Notarfranchi, Laura
    Gonzalez, Carmen
    Teresa Cedena, Maria
    Barrio, Santiago
    Jose Calasanz, Maria
    Mateos Manteca, Maria-Victoria
    Rosinol, Laura
    Jose Lahuerta, Juan
    Blade, Joan
    San-Miguel, Jesus
    Puig, Noemi
    Paiva, Bruno
    Martinez-Lopez, Joaquin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S134 - S134
  • [40] Kinetics and Biology of Circulating Tumor Cells (CTCs) and Measurable Residual Disease (MRD): Two Dynamic High-Risk Clones in Multiple Myeloma (MM)
    Guerrero, Camila
    Termini, Rosalinda
    Garces, Juan-Jose
    Jose Calasanz, Maria
    Rios, Rafael
    Cabezudo, Elena
    Rosinol, Laura
    Joan, Bargay
    Perez-Montana, Albert
    Oriol Rocafiguera, Albert
    Cabanas Perianes, Valentin
    Najera, Maria-Josefa
    Garcia, Esther Gonzalez
    Ocio, Enrique M.
    Sureda Balari, Anna Maria
    De Arriba, Felipe
    Hernandez Garcia, Miguel Teodoro
    Garcia, Antonio
    Martinez-Lopez, Joaquin
    Blanchard, Maria-Jesus
    Gonzalez Perez, Marta Sonia
    Iglesias, Rebeca
    Orfao, Alberto
    Victoria Mateos, Maria
    Lahuerta Palacios, Juan Jose
    Blade, Joan
    San-Miguel, Jesus
    Cedena, Maria T.
    Puig, Noemi
    Paiva, Bruno
    BLOOD, 2023, 142
12345